SOLVSolventum

$91.53

The financials

Solventum by the numbers

Solventum (SOLV) reported revenue of $2.21B in Q2 2026 (quarter ended June 30, 2026), up 2.2% from the same quarter a year earlier. That came with a gross margin of 58% and net income of $92M (4.2% of revenue). For the full year FY2025, revenue was $8.32B (+0.9% year on year) and net income $1.56B. Its largest segment in 2026-Q2 was Med Surg at $537M, 42% of the disclosed total, just ahead of Dental Solutions at 31%.

Solventum income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Revenue$2.21B$2.16B+2.2%
Gross profit$1.29B$1.18B+9.4%
Operating income$181M$214M−15%
Net income$92M$90M+2.2%
Diluted EPS$0.53$0.51+3.9%
Revenue by segment, 2026-Q2, as reported to the SEC
OperatingRevenueShare
Med Surg$537M42%
Dental Solutions$396M31%
Health Information Systems$354M28%

Business Segments

Revenue split by operating segment, from SEC XBRL filings.

Latest period: Q2 2026Total $1.29B (+7.9%)
Dental Solutions grew +17% year on yearPurification And Filtration -100% year on year
  • Med Surg$537.0MQoQ +8.0%year on year +15%
  • Dental Solutions$396.0MQoQ +12%year on year +17%
  • Health Information Systems$354.0MQoQ +3.5%year on year +4.4%
  • Purification And Filtration$0.00QoQ -year on year -100%
Segment sum = 58% of reported consolidated revenue (partial disaggregation) · Latest source: 10-Q filed 2026-08-05, SEC EDGAR